Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience

The optimal duration of lenalidomide (Len) maintenance for patients with multiple myeloma (MM) after autologous stem cell transplantation (autoHCT) is unknown. We conducted a retrospective single-center analysis of adult MM patients that received upfront autoHCT between 2005 and 2021, followed by si...

Full description

Saved in:
Bibliographic Details
Published in:American journal of hematology 2023-10, Vol.98 (10), p.1571-1578
Main Authors: Pasvolsky, Oren, Milton, Denái R, Masood, Adeel, Sami, Sophiya S, Tanner, Mark R, Bashir, Qaiser, Srour, Samer, Saini, Neeraj, Lin, Paul, Ramdial, Jeremy, Nieto, Yago, Saeed, Arsalan, Lee, Hans C, Patel, Krina K, Kebriaei, Partow, Thomas, Sheeba K, Weber, Donna M, Orlowski, Robert Z, Shpall, Elizabeth J, Champlin, Richard E, Qazilbash, Muzaffar H
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Autografts
Chromosome aberrations
Clinical trials
Cytogenetics
Dexamethasone - therapeutic use
Hematology
Hematopoietic Stem Cell Transplantation
Humans
Immunotherapy
Lenalidomide - therapeutic use
Malignancy
Middle Aged
Multiple myeloma
Multiple Myeloma - diagnosis
Multiple Myeloma - drug therapy
Retrospective Studies
Solid tumors
Stem Cell Transplantation
Stem cells
Targeted cancer therapy
Transplantation, Autologous
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The optimal duration of lenalidomide (Len) maintenance for patients with multiple myeloma (MM) after autologous stem cell transplantation (autoHCT) is unknown. We conducted a retrospective single-center analysis of adult MM patients that received upfront autoHCT between 2005 and 2021, followed by single-agent Len maintenance. A total of 1167 patients were included with a median age of 61.4 (range 25.4-82.3) years, and high-risk chromosomal abnormalities in 19%. Median duration of maintenance was 22.3 (range 0.03-139.6) months. After a median follow-up of 47.9 (range 2.9-171.7) months, median PFS and OS for the entire cohort were 56.6 (95% CI 48.2-61.4) months and 111.3 (95% CI 101.7-121.5) months, respectively. In MVA, high-risk cytogenetics was associated with a worse PFS (HR 1.91) and OS (HR 1.73) (p 
ISSN:0361-8609
1096-8652
1096-8652
DOI:10.1002/ajh.27029